Quarterly ResultMay 6, 2026, 04:18 PM
Sarepta Q1 GAAP Net Income $331M; Operating Income $358.4M
AI Summary
Sarepta Therapeutics reported Q1 2026 GAAP net income of $331.0 million and GAAP operating income of $358.4 million, marking a significant turnaround from losses in Q1 2025. Total revenues were $730.8 million, a slight decrease year-over-year, primarily due to lower ELEVIDYS sales from an updated label. The company also announced positive early clinical data from its siRNA pipeline for FSHD1 and DM1, advanced enrollment in ENDEAVOR Cohort 8 for ELEVIDYS, and submitted sNDAs for traditional approval of AMONDYS 45 and VYONDYS 53. Sarepta reiterated its full-year 2026 guidance for total net product revenues of $1.2 - $1.4 billion.
Key Highlights
- GAAP Net Income was $331.0 million, a significant improvement from $(447.5) million loss in Q1 2025.
- Non-GAAP Net Income reached $385.4 million, up from $(332.5) million loss in Q1 2025.
- Total Revenues were $730.8 million, a 2% decrease from $744.9 million in Q1 2025.
- Net Product Revenues totaled $330.5 million, including $102.0 million from ELEVIDYS.
- GAAP Diluted EPS was $2.88, a turnaround from $(4.60) loss in Q1 2025.
- SiRNA pipeline (SRP-1001, SRP-1003) showed dose-dependent drug exposure and early biomarker effects.
- Submitted sNDAs for AMONDYS 45 and VYONDYS 53 for traditional approval.
- Reiterated FY 2026 total net product revenue guidance of $1.2 - $1.4 billion.
Price Impact
More from SRPT